What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide studied for its role in metabolism and the body’s response to exercise. It has drawn interest for weight- and bone-related effects. It is not an FDA-approved drug.
What the evidence shows
MOTS-c research is at an early stage and mostly preclinical. Human trial evidence for obesity or osteoporosis is limited, and its safety and effectiveness in people are not established.
Is it legal?
MOTS-c is not FDA-approved. In April 2026 it was removed from FDA Category 2 but not moved to the approved Category 1 list, so legal compounding is not authorized; the PCAC reviews it on July 23, 2026.
Will MOTS-c become legal in 2026?+
Is “research-grade” MOTS-c the same as a medicine?+
Primary sources: FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. MOTS-c is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.